STATEN ISLAND, N.Y., May 4, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics ...
Poster will feature in vivo efficacy profile of one of Augustine’s HDAC6 inhibitor development candidatesLEUVEN, Belgium –2 June 2026 – Augustine ...
Poster to be presented at ADA 2026 on weight loss induced by MTRX31 in an industry-standard preclinical model of ...
American Society of Gene and Cell Therapy 29th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference 3rd International Conference on Ureagenesis Defects and Allied ...
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results